Kyriacos Mitrophanous (Oxford Biomedica plc (LSE: OXB))

Mitrophanous, Kyriacos (Oxford BioMedica 201710 CSO + BIA Board Member)

	Organisation	Oxford Biomedica plc (LSE: OXB)
	Group	Oxford Biomedica (Group)
	Product	gene therapy

BioIndustry Assocation (BIA). (10/23/17). "Press Release: BIA Announces New Appointments to the BIA Board".

Following the BIA AGM last week, the Association has announced the new members who have been elected to its Board. The AGM took place on Thursday 12th October at the QEII Centre as part of the BIA’s annual UK Bioscience Forum and the new board members were voted for by the BIA’s membership in the weeks leading up to the meeting.

There were four corporate places and one ‘other’ member place to be filled and the new Board members who were elected and will join the Board from January 1st 2018 for a three year term are:

Corporate Board Members:

Jane Dancer, CBO of F-star

Jane will bring to the BIA her experience of business development, finance, IP, communications and alliance management from the perspective of both large and small companies, including through periods of rapid growth and change.

Jackie Hunter, CEO of Benevolent Bio

Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development.

Kyriacos Mitrophanous, CSO of Oxford BioMedica

Kyriacos will bring his extensive knowledge of the key players in the field of gene and cell therapy. He has first-hand experience of the challenges in establishing and developing an SME in the UK bioindustry and has been involved in, and able to influence, many critical decisions in progressing both the scientific direction and business strategy.

Keith Thompson, CEO of Cell and Gene Therapy Catapult (re-elected)

Keith will continue to bring significant manufacturing and commercial experience to the BIA Board. In addition, experience of running a part of the NHS and working with the highest levels of Government has given him valuable insights that have helped inform BIA policy and strategy.

Other Board Member:

Sue Charles, Managing Partner at Instinctif Partners

Sue will bring her wide experience as an entrepreneur, creative thinker and communications professional to the Board, to help the BIA continue expanding its reach and impact, and in steering a successful future for UK biotech, as it navigates the unchartered waters of a post-Brexit environment and beyond.

The Directors standing down at the AGM were: David Hipkiss, Andrew Lightfoot, Tim Watts and Sam Williams.

Chair of the Board, Dr Jane Osbourn said: “The BIA Board does a fantastic job of providing strategic direction for the Association on behalf of our members and I look forward to working with the new members over the coming year. It is a testament to the strength of the organisation that leading figures want to serve on the Board. We had an excellent range of candidates up for election this year and I would encourage all of those who were not successful this time around to look at standing next year. I would also like to thank those Directors leaving the Board for their dedicated and impactful service over the years.”

For more information on the BIA Board – go to the about us section on the BIA website https://www.bioindustry.org/about-us.html

Ends

Notes to editors

Contact:

Ed Sexton,
BIA Communications and Media Relations Manager:
esexton@bioindustry.org
0207 630 2196

About the UK BioIndustry Association (BIA)

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

For further information, please go to www.bioindustry.org and twitter.com/BIA_UK

Record changed: 2017-10-23

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)